论文部分内容阅读
目的 :观察尼莫通对急性脑梗死 (ACI)的治疗作用。方法 :80例ACI患者随机分为两组 ,尼莫通治疗组 (A组 ) 4 0例应用尼莫通 1 0mg静滴 ,每日 1次 ,共 1 4天 ;低分子右旋糖酐组 (B组 ) 4 0例应用低分子右旋糖酐 50 0ml,方法与疗程同A组。分别于治疗前与治疗 1疗程后作神经功能缺损评分 ;同时观察血液动力学、心电图、梗死灶体积大小等指标的变化以评定临床疗效。结果 :治疗后A组有效率 95 0 0 % ,明显高于B组 70 0 0 % ,(P<0 .0 1 )。且A组治疗后血浆粘度、全血高切粘度、全血低切粘度及纤维蛋白原定量均显著下降 ;且CT扫描病灶比治疗前缩小较B组明显。结论 :尼莫通能明显改善ACI患者的血流动力学指标 ,且安全 ,疗效可靠 ,可作为ACI治疗的一种新选择。
Objective: To observe the therapeutic effect of nimotop on acute cerebral infarction (ACI). Methods: Eighty ACI patients were randomly divided into two groups. The nimotop group (group A) 40 cases were treated with nimotop 10 mg intravenously once daily for 14 days. The low molecular dextran group (group B) ) 40 cases of low molecular weight dextran 50 0ml, method and treatment with the A group. Respectively, before and after treatment for 1 course of treatment for neurological deficit score; the same time, hemodynamic, electrocardiogram, infarct size and other indicators of change in order to assess the clinical efficacy. Results: After treatment, the effective rate of group A was 95 0 0%, which was significantly higher than that of group B 70 0 0% (P 0 01). After treatment, the plasma viscosity, whole blood high shear viscosity, whole blood low shear viscosity and fibrinogen quantification decreased significantly; and the CT scan lesion was smaller than that before treatment. Conclusion: Nimotop can significantly improve the hemodynamic parameters of patients with ACI, and its safety and curative effect are reliable. It can be used as a new choice for ACI.